---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-011088"
form_type: "8-K"
ticker: "MXCT"
cik: "0001287098"
company_name: "MAXCYTE, INC."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:10:16.091438+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MaxCyte Q2 revenue up 15% to $10.4M; core revenue down 9% to $7.6M; SPL revenue jumps 279%

## Summary
- Total revenue $10.4M (+15% YoY); core business revenue $7.6M (-9% YoY); SPL program-related revenue $2.9M (+279% YoY).
- Net loss narrowed to $9.4M from $10.5M in Q2 2023; EBITDA loss $10.9M vs $12.0M.
- Signed five new SPLs YTD including Legend Biotech (May) and Be Biopharma (Mar); total SPL partners now 28.
- Ended Q2 with $199.8M cash; now expects FY2024 ending cash at least $180M, up from prior $175M guidance.
- Raised FY2024 SPL revenue guidance to ~$6M; core business revenue guidance reaffirmed flat to 5% growth.

## SEC filing metadata
- accession: 0001558370-24-011088
- form_type: 8-K
- ticker: MXCT
- cik: 0001287098
- company_name: MAXCYTE, INC.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1287098/000155837024011088/0001558370-24-011088-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1287098/000155837024011088/mxct-20240806x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-011088
- JSON: https://secwatch.observer/filing/0001558370-24-011088.json
- Plain text: https://secwatch.observer/filing/0001558370-24-011088.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.